发明名称 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR
摘要 The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
申请公布号 US2016009639(A1) 申请公布日期 2016.01.14
申请号 US201514860593 申请日期 2015.09.21
申请人 Metabasis Therapeutics, Inc. 发明人 Gomez-Galeno Jorge E.;Reddy Raja K.;van Poelje Paul D.;Lemus Robert Huerta;Nguyen Thanh Huu;Grote Matthew P.;Dang Qun;Hecker Scott J.;Mali Venkat Reddy;Chen Mingwei;Sun Zhili;Boyer Serge Henri;Li Haiqing;Craigo William
分类号 C07C309/15 主分类号 C07C309/15
代理机构 代理人
主权项 1. A compound of general formula (I) wherein: D is selected from carbocyclic aryl, C1-8-alkyl carbocyclic aryl, heteroaryl, cycloalkyl, or heterocyclyl, wherein said group is optionally substituted with L and, optionally, one or more additional substituents independently selected from —NR10R10, —OR9, —SR9, —S(O)R9, —SO2R9, —NR9SO2R10, —NR9SO2R10, —SO2RNR10R10, —CONR10R10, —NR9COR10, —OC(O)NR10R10, —CH2NR10R10, —OC(O)R9, —C(O)R9, or —COOR9; or two adjacent positions on D are substituted with the group —(CR11R11)a—O—(CR11R11)c—O—, wherein said —(CR11R11))—O—(CR10R10)c—O— group forms a 5- or 6-membered ring; wherein a is 0 or 1; wherein c is 1 or 2; and wherein each R11 is independently selected from hydrogen, C1-6-alkyl, or fluoro; wherein R9 is independently selected from hydrogen, optionally substituted aralkyl, C1-6-alkyl or optionally substituted aryl; andwherein each R10 is independently selected from hydrogen, optionally substituted C1-6-alkyl, optionally substituted aryl or R10R10 together with the N to which they are attached form a 3 to 8-membered optionally substituted heterocyclic ring; wherein said heterocyclic ring contains at least one C atom; wherein said heterocyclic ring optionally contains one or two further heteroatoms independently selected from nitrogen, oxygen, and sulfur, and wherein said heterocyclic ring optionally contains 0, 1, or 2 double bonds; L is a group selected from hydrogen, carbocyclic aryl, CF3, carbocyclic aryloxy-, carbocyclic arylalkoxy-, carbocyclic arylalketyl-, carbocyclic arylketyl-, carbocyclic aryl-N(R12)—, heteroaryl, heteroarylalketyl, —N(R12)—, cycloalkyl, cycloalkylalkyl, cycloalkylalkoxy-, cycloalkyloxy-, cycloalkylketyl-, cycloalkylalketyl-, cycloalkyl-N(R12)—, heterocyclyl, heterocyclyloxy-, heterocyclylalkyoxy-, heterocyclylkeetyl-, heterocyclylalketyl-, heterocyclyl-N(R12)—, alkenyl, cycloalkenyl or alkynyl, furanyl, thiophenyl, oxazolyl, thiazolyl, phenyl, benzyl, indenyl, pyridyl, pyrmidinyl, benzofuranyl, indolyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, furanyl-oxy-, thiophenyl-oxy-, oxazolyl-oxy-, thiazolyl-oxy-, phenyl-oxy-, pyridyl-oxy-, pyrimidinyl-oxy-, benzofuranyl-oxy-, benzothiophenyl-oxy-, benzimidazolyl-oxy-, phenyl-N(R12)—, pyridyl-N(R12)-pyrimidinyl-N(R12)—, benzofuranyl-N(R12)—, benzothiophenyl-N(R12)—, benzimidazolyl-N(R12)—, C3-8-cycloalkyloxy, C4-8-cycloalkenyloxy, C1-6-alkoxy, C3-8-cycloalkyl-N(R12)—, or C4-8-cycloalkenyl-N(R12)—, wherein R12 is selected from hydrogen or C1-3-alkyl;wherein L, excluding hydrogen, is optionally substituted with one, two, or three groups selected from halogen, CF3, hydroxyl, amido, optionally substituted C1-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted C2-6-alkynyl, optionally substituted C3-6-cycloalkyl, optionally substituted C4-8-cycloalkenyl, optionally substituted C1-8-alkyoxy, optionally substituted C3-8-alkylthio-, optionally substituted C3-8-cycloalkylalkoxy, optionally substituted C3-8-cycloalkylalkylthio, —NO2, —CN, —NR10R10, —OR9, —SR9, —S(O)R9, —SO2R9, —NR9SOR10, —NR9SO2R10, —SO2NR10R10, —CONR10NR10, —NR9COR10, OC(O)NR10R10, —CH2NR10R10, —OC(O)R9, —C(O)R9 or —COOR9, phenyl, phenyl-oxy-, phenyl-C1-6-alkyl-oxy-,R12 is selected from hydrogen or C1-3-alkyl; Z is a group selected from -isoxazol-3,5-diyl- or —C(O)N(R2)—,R2 is a group selected from hydrogen or C1-8-alkyl; or, together, Z and D form a group wherein the ring A1 is a 4-8 membered heterocyclic ring, optionally containing an additional heteroatom selected from oxygen, nitrogen or sulfur, wherein said A′ is optionally substituted with a group selected from C5-4-alkyl- or C3-5-cycloalkyl-; Y is a group selected from —C(O)—, —O—, —NR26—, —S—, —S(O)—, S(O)2—, —CR26R27— or —CF2—,R26 is a group selected from hydrogen, or C1-6-alkyl, C1-6-perfluoroalkyl or fluoro; R1 is a group selected from hydrogen, fluoro or C1-6-alkyl optionally substituted with fluoro up to perfluoro, or R1 is absent, Y is —CR27, wherein said —CR27 is attached by a double bond to the C to which R1 would otherwise be attached if present;R27 is a group selected from hydrogen, C1-6-alkyl, hydroxyl, or fluoro; E is a group selected from C1-12-alkyl, C2-12-alkenyl, C2-12-alkynyl, C3-8-cycloalkyl, C4-8-cycloalkenyl, carbocyclic aryl, heteroaryl, methoxyphenyl-, ethoxyphenyl-, propyloxyphenyl-, isopropyloxyphenyl-, butyloxyphenyl-, t-butyloxyphenyl-, isobutyloxyphenyl-, pentyloxyphenyl-, isopentyloxyphenyl-, t-butylvinylphenyl, (S)-4-t-butylcyclohexenylphenyl, (R)-4-t-butylcyclohexenylphenyl, 4,4-dimethylcyclohexadienylphenyl, 4,4-dimethylcyclohexenylphenyl, cyclohexenylphenyl, 4,4-diethylcyclohexenylphenyl, 4,4-dipropylcyclohexenylphenyl, cis-4-t-butylcyclohexylphenyl, trans-4-t-butylcyclohexylphenyl, 4-t-butylphenylphenyl or neopentyloxyphenyl-; wherein each group is optionally substituted with one to six groups independently selected from halogen, —CN, —C1-6-alkyl, —CHF2, —C(CH3)3—CF3, —OCF3, —OCHF2, —OCH2CF3, —OCF2CHF2, —SCF3, —OR9, —NR10R10, —SR9, —S(O)R9, —S(O)2R9, —C(O)NR10R10, —OC(O)NR10R10, —NR9C(O)R9, —OCH2C(O)NR10R10, —C(O)R9, or —C(O)OR9, optionally substituted C3-8-cycloalkyl, optionally substituted C4-8-cycloalkenyl, optionally substituted phenyl or optionally substituted five- or six-membered heteroaryl; X is a group selected from phenylene, heterocyclic monoarylene, C5-8-cycloalkylene or C5-8-cycloalkenylene; wherein X is optionally substituted with one or two groups independently selected from halogen, —CN, —CF3, —OCF3, —OCHF2, —NO2, —OR30, C1-6-alkyl, C2-6-alkenyl, or C1-6-alkynyl; wherein, R30 is hydrogen or C1-6-alkyl; M is a group selected from —C(O)NR30—, —NR30C(O)—, —S(O)2NR30—, —NR30S(O)2—, —C(S)NR30—, —NR30C(S)—, —O—, or —S—;R30 is a group independently selected from hydrogen or C1-6-alkyl optionally substituted with fluoro up to perfluoro; T is a group selected from —(CHR30)—, phenylene or five- or six-membered heterocyclic monoarylene, each optionally substituted; wherein when n=0, T is absent and A is connected directly to M; A is a group selected from —(CHR36)mR5, —(CHR36)mSO3H, or —(CHR36)mQSO2R39;R5 is —P(O)(GR21)G′R21;R36 is a group selected from hydrogen, C1-6-alkyl, hydroxyl, fluoro, or —(CH2)pOR38;p is 0 or 1;n is 0, 1, 2, or 3;m is 1, 2 or 3;wherein n+m is 1, 2, or 3;R38 is a group selected from hydrogen or optionally substituted C1-3-alkyl;R39 is a group selected from —OH, —NHOH, —NH2;Q is a group selected from oxygen or NR43;R43 is a group independently selected from C1-6-alkyl or hydrogen; andG and G′ are each independently selected from —O— or NRv—; wherein:when G and G′ are both —O—, R21 attached to —O— is independently selected from —H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted —CH2-heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, —C(Rz)2OC(O)NRz2, —NRz—C(O)—Ry, —C(Rz)2—OC(O)Ry, —C(Rz)2—O—C(O)ORy, —C(Rz)2OC(O)SRy, -alkyl-S—C(O)Ry, -alkyl-S—S-alkylhydroxy, or -alkyl-S—S—S-alkylhydroxy; orwhen G and G′ are both —NRv—, then R21 attached to —NR10— is independently selected from —H, —[C(Rz)2]r—COORy, —C(Rx)2—COORy, —[C(Rz)2]rC(O)SRy, or -cycloalkylene-COORy; orwhen G is —O— and G′ is NRv, then R21 attached to —O— is independently selected from —H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH2-heterocycloalkyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, —C(Rz)2OC(O)NRz2, —NRz—C(O)—Ry, —C(Rz)2—OC(O)Ry, —C(Rz)2—O—C(O)ORy, —C(Rz)2OC(O)SRy, -alkyl-S—C(O)Ry, -alkyl-S—S-alkylhydroxy, or -alkyl-S—S—S-alkylhydroxy; and R21 attached to —NRv— is independently selected from —H, —[C(Rz)2]r—COORy, —C(Rx)2—COORy, —[C(Rz)2]r—C(O)SRy, or -cycloalkylene-COORy; wherein if both R21 are alkyl, at least one is higher alkyl; orwhen G and G′ are independently selected from —O— and —NR10—, then R21 and R21 together form a cyclic group comprising -alkyl-S—S-alkyl or R21 and R21 together are the group wherein:V, W, and W′ are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; andJ is —CHRzOH, —CHRzOC(O)Ry, —CHRzOC(S)Ry, —CHRzOC(S)ORy, —CHRzOC(O)SRy, —CHRzOCO2Ry, —ORz, —SRz, —CHRzN3, —CH2aryl, —CH(aryl)OH, —CH(CH═CHRz2)OH, —CH(C≡CRz)OH, —Rz, —NRz2, —OCORy, —SCORy, —SCO2Ry, —NHCORz, —NHCO2Ry, —CH2NHaryl, —(CH2)r—ORz or —(CH2)r—SRz; ortogether V and J are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon; ortogether V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms or carbon substituted by hydrogen and substituted with one substituent selected from hydroxyl, acyloxy, alkyoxycarbonloxy, alkylthiocarbonyloxy or aryloxycarbonyloxy which is attached to one of said carbon atoms that is three atoms from a G attached to the phosphorous; ortogether J and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl; ortogether W and W′ are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon, where V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl;Rz is Ry or —H;Ry is alkyl, aryl, heterocycloalkyl, or aralkyl;Rx is independently selected from —H or alkyl, or together Rx or Rx form a cycloalkylene group;Rv is —H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, lower acyl, C1-6-perfluoroalkyl or NH(CR43R43)fCH3;f is 0, 1, or 2;r is 2 or 3; wherein,V, J, W, W′ are not all —H,when J is —Rz, then at least one of V, W, and W′ is not —H, alkyl, aralkyl, or heterocycloalkyl; andpharmaceutically acceptable salts, cocrystals and prodrugs thereof.
地址 La Jolla CA US